Top 50 Biotech Startup Investors in Sweden in April 2025

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

Länsförsäkringar is a Swedish group of public insurance companies.

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Imprimatur Capital Fund Management is a venture capital firm focusing on high-technology at an early stage in its commercial development. We invest in start-up technology businesses which are based on innovative intellectual property, are led by strong teams and have high international growth potential.Imprimatur Capital Fund Management, based inLatvia, manages seed and start-up funds with investors including the Latvian Guarantee Agency, other institutional investors and some private investors. The company source investment opportunities primarily from the Baltic/Nordic/Russia region.Imprimatur Capital Fund Management is a partner firm of Imprimatur Capital Ltd, headquartered in London and with investment operations in Europe, Russia, Asia Pacific, Latin America and the US.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

We help great minds unleash their full potential!

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

EIR Ventures is a new Life Science Venture Group in the Nordics.

GOBIA Enterprises is owned by Jan G Smith who has been active in the pharmaceutical industry.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Colibri Ventures invest in early-stage life science companies and help accelerate their innovations into commercial products.

TPG Growth was founded in 2007 to specialize in growth equity and middle-market buyout opportunities. Taking a long-term and hands-on approach to partnership, we identify unique companies across the U.S., Europe, Africa, and Asia and help them achieve their full potential. We can assist at all stages of a company’s growth, from its inception to itsinternational expansion, by drawing on our geography-specific experience and expert global operational resources from the TPG platforms. TPG Growth manages more than $7 billion in assets across a variety of sectors including media, technology, and industrials.

Almi Invest GreenTech is a venture capital company and an active start-up investor.

Karolinska Institutet Holding is a subsidiary of KI Holding AB.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Phase2Phase Biopharma is a consulting company that offers CMC strategies, CRO, CMO, CDMO sourcing, CMC project management, and QA services.

PULS is specialized on DIN rail power supplies for industrial applications. We set standards in terms of efficiency, reliability, size and life time.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.

Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.

Porte Monnaie is an early and active investor for startup companies and passive investors in listed companies with growth potential. Porte-Monnaie's mission is to invest in Swedish companies.

Kale United offers a portfolio of over 75+ plant-based game changers

Ferd er et familieeid investeringsselskap som er eid av femte og sjette generasjon Andresen.

Social Starts is a $60M+ venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds.

GU Ventures build businesses out of groundbreaking ideas that help shape a better tomorrow. Our passionate team of company builders, financial experts, IP and legal talent ensure success for our companies.

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.

Joyance Partners is the first venture fund supporting companies that deliver Delightful Moments derived from science - a new, transformative cycle of human experience that we see as one of the greatest investment opportunities in decades.

Knutsson Holdings AB is an family owned private equity firm.

Pär Gellerfors

On Sätila Holding, They are constantly looking for exciting new business ideas. They invest in start up, buy-out, expansion and reorganization. They go in as partners and their investments tend to be between 1 and 10 million.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.